Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.

Slides:

Advertisements

Similar presentations

Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.

Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

A R ANDOMIZED C ONTROLLED T RIAL OF A P ACLITAXEL -E LUTING S TENT V ERSUS A S IMILAR B ARE -M ETAL S TENT IN S APHENOUS V EIN G RAFT L ESIONS Journal.

From: Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients: A Three-Dimensional Volumetric Intravascular Ultrasound.

From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.

Nat. Rev. Cardiol. doi: /nrcardio

Jose M. de la Torre Hernández … in behalf of the 3D investigators

A-F. Intracardiac echocardiography images

Figure 1 Flow diagram of systematic review

Harvard Clinical Research Institute, Boston, US

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Relation of aortic regurgitation to all-cause mortality in the transcatheter aortic valve replacement (TAVR) as-treated population of the Placement of.

Testing algorithm for patients with mild stenoses

Multivessel PCI: Pearls of Wisdom (?) for Success

LoopMaster-Sochman snare (Andramed Medical Devices, Reutlingen, Germany). When a loop snare cannot be passed around the end of a foreign body, the curved.

The MASS-DAC Study.

Cardiac computed tomography (CT) scan techniques

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Robert A. Guyton, MD The Annals of Thoracic Surgery

Volume 54, Issue 1, Pages (August 2009)

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Meta-Analysis of Three Randomized Trials and Nine Observational Studies Comparing Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected.

Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug- Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment.

Practicing sit-to-stand/sit-from-stand transfers using a variety of seating surfaces will better simulate a patient's home and community environment. Source:

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Extension of survival in months for various subgroups of patients with chronic stable angina treated by surgery as compared with those treated by medicine.

Extension of survival in months for various subgroups of patients with chronic stable angina treated by surgery as compared with those treated by medicine.

Currently available simulators. A

DES Should be Used as the Default Stent in ACS!

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

New Frontiers in Cardiology

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Circ Cardiovasc Interv

Comparison of prevalence of uncovered struts between ZES and EES groups. Comparison of prevalence of uncovered struts between ZES and EES groups. Scatter plot.

Catheter-Based Treatment of Coronary Artery Disease

TAXUS II and IV: two-year follow-up

Bern-Rotterdam Registry Published in the Lancet

Robert A. Guyton, MD The Annals of Thoracic Surgery

Nat. Rev. Cardiol. doi: /nrcardio

Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

American College of Cardiology Presented by Dr. Stephan Windecker

Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery Konstantinos.

REALITY: 8 month results

Nat. Rev. Cardiol. doi: /nrcardio

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Presented at ACC 2003 Late Breaking Clinical Trials

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome Abhishek Sharma, MD,

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Figure 1 Milestones in coronary angioplasty

(p = 0.32 for noninferiority)

Drug-eluting stents for in-stent restenosis

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

(p for non-inferiority < 0.001)

American College of Cardiology Presented by Dr. Adnan Kastrati

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting stents. EES, everolimus-eluting stents; E-ZES, Endeavor zotarolimus-eluting stent; PES, paclitaxel-eluting stent; R-ZES, Resolute zotarolimus-eluting stent; SES, sirolimus-eluting stent. (Results from Bangalore S, Fusaro M, Amoroso N, et al. Response to letter regarding article, “Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison Analysis of 117,762 patient-years of follow-up from randomized trials.” Circulation. 2013;127:e447.) Source: In-Stent Restenosis, Interventional Cardiology, 2e Citation: Samady H, Fearon WF, Yeung AC, King III SB. Interventional Cardiology, 2e; 2017 Available at: http://accesscardiology.mhmedical.com/DownloadImage.aspx?image=/data/books/1986/intercard2_ch33_f010.png&sec=165115767&BookID=1986&ChapterSecID=165115695&imagename= Accessed: November 08, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved